C83.3
Diffuse large B-cell lymphoma
Clinical Classification Guidelines
Inclusion Terms
- Anaplastic diffuse large B-cell lymphoma
- CD30-positive diffuse large B-cell lymphoma
- Centroblastic diffuse large B-cell lymphoma
- Diffuse large B-cell lymphoma, subtype not specified
- Immunoblastic diffuse large B-cell lymphoma
- Plasmablastic diffuse large B-cell lymphoma
- T-cell rich diffuse large B-cell lymphoma
Excludes Type 1
- mediastinal (thymic) large B-cell lymphoma (C85.2-)
- mature T/NK-cell lymphomas (C84.-)
Medical Intelligence & Overview
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing type of non-Hodgkin lymphoma that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This lymphoma can develop in lymph nodes throughout the body and may also affect other tissues. Its aggressive nature means it often requires prompt treatment, but many patients respond well to therapy. Understanding the characteristics of DLBCL can help in recognizing the condition and seeking appropriate medical care.
Causes & Symptoms
Clinical Causes: Genetic mutations in B-cells that lead to uncontrolled growth Infections, such as certain viruses (e.g., Epstein-Barr virus, HIV) Conditions that weaken the immune system, like HIV/AIDS or receiving immunosuppressive therapy Environmental exposures, though specific links are not well established Previous cancer treatments such as chemotherapy or radiation therapy
Key Symptoms: Swollen lymph nodes, often painless and enlarged Unexplained weight loss Fever that persists without an infection Night sweats Fatigue and weakness Loss of appetite Pain or pressure in affected areas, depending on where lymphoma develops Enlargement of organs, such as the spleen or liver, causing discomfort
Diagnostic & Treatment
Diagnosis Path: Diagnosis of diffuse large B-cell lymphoma typically involves multiple steps:
Treatment Protocols: Treatment strategies for diffuse large B-cell lymphoma depend on factors like disease stage and patient health, but generally include:
Clinical Advice & FAQs
Billing Guidance
Is C83.3 a billable ICD-10 code?
Yes, C83.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.3?
Clinical documentation must specify the nature of Diffuse large B-cell lymphoma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference